ALDX · Aldeyra Therapeutics, Inc. · Metrics
Market Cap
$70.88M
Shares
60.33M
Volume · Oct 5
7.03M
Avg daily vol (3M)
1.13M
ALDX metrics
50 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.92
Market cap
$70.88M
Price action
20 metricsPrice change (1W)
-2.9%
Price change (30D)
-24.0%
Price change (3M)
-48.5%
Price change (6M)
-29.5%
Price change (YTD)
-77.4%
Price change (1Y)
-78.0%
Trailing year
Price change (5Y)
-86.8%
52-week high
$5.74
52-week low
$1.16
Change from 52-week high
-79.6%
Change from 52-week low
+0.9%
Annualized volatility
114.6%
Annualized volatility (3M)
72.0%
Beta
1.3
RSI (14D)
37.3
Price vs SMA 50
-19.9%
Price vs SMA 200
-56.3%
Avg volume (3M)
1.04M
Relative volume
2.2
Average dollar volume
$1.65M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
60.33M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.9
reciprocal yield 53.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-32.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2023-05-04
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$24.07M
Net income (TTM)
−$23.05M
Trailing 12 months
Diluted EPS (TTM)
$-0.38
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-60.8%
Return on assets
-48.5%
Debt / equity
—
Current ratio
4.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.9
Interest coverage
-16.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$45.09M
Total assets
$47.54M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$22.02M
Capital expenditures (TTM)
$0
R&D (TTM)
$15.63M
SG&A (TTM)
—
Stock compensation (TTM)
$4.33M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
107
13F filer change QoQ
-21
Institutional ownership
61.7%
Short interest
3 metricsShort interest
6.0%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
59 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—